Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice
Author
Aggarwal, CharuRolfo, Christian D
Oxnard, Geoffrey R
Gray, Jhanelle E
Sholl, Lynette M
Gandara, David R
Date
2020-09-11Journal
Nature Reviews. Clinical OncologyPublisher
Springer NatureType
ArticleOther
Metadata
Show full item recordAbstract
Upfront tumour genotyping is now considered an essential step in guiding treatment decision-making in the management of patients with advanced-stage non-small-cell lung cancer (NSCLC) in light of the ever-expanding toolbox of targeted therapies and immune-checkpoint inhibitors. However, genotyping of tumour biopsy samples is not feasible for all patients and, therefore, genomic analysis of circulating tumour DNA (ctDNA) has emerged as a compelling non-invasive option. Current guidelines universally recommend genotyping and support the use of ctDNA testing in certain settings, although they often omit the detail necessary for integrating these tests into clinical care on an individual basis. In this Perspective, we describe the rationale, promise and challenges associated with ctDNA-based NSCLC genotyping and suggest a framework for the implementation of these assays into routine clinical practice. We also offer considerations for the interpretation of ctDNA genotyping results, which, particularly when using next-generation sequencing panels, can be nuanced. Through the addition of this new approach to clinical practice, we propose that oncologists might finally be able to utilize effective genotyping in nearly all patients with advanced-stage NSCLC. © 2020, Springer Nature Limited.Keyword
Carcinoma, Non-Small-Cell Lung--geneticsCirculating Tumor DNA--genetics
Genotyping Techniques
Identifier to cite or link to this item
http://hdl.handle.net/10713/14323ae974a485f413a2113503eed53cd6c53
10.1038/s41571-020-0423-x
Scopus Count
Collections
Related articles
- The Role of Circulating Tumor DNA in Lung Cancer: Mutational Analysis, Diagnosis, and Surveillance Now and into the Future.
- Authors: Scilla KA, Rolfo C
- Issue date: 2019 Jun 15
- Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.
- Authors: Li BT, Janku F, Jung B, Hou C, Madwani K, Alden R, Razavi P, Reis-Filho JS, Shen R, Isbell JM, Blocker AW, Eattock N, Gnerre S, Satya RV, Xu H, Zhao C, Hall MP, Hu Y, Sehnert AJ, Brown D, Ladanyi M, Rudin CM, Hunkapiller N, Feeney N, Mills GB, Paweletz CP, Janne PA, Solit DB, Riely GJ, Aravanis A, Oxnard GR
- Issue date: 2019 Apr 1
- Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
- Authors: Guo Q, Wang J, Xiao J, Wang L, Hu X, Yu W, Song G, Lou J, Chen J
- Issue date: 2018 Aug 28
- Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.
- Authors: Zugazagoitia J, Ramos I, Trigo JM, Palka M, Gómez-Rueda A, Jantus-Lewintre E, Camps C, Isla D, Iranzo P, Ponce-Aix S, García-Campelo R, Provencio M, Franco F, Bernabé R, Juan-Vidal O, Felip E, de Castro J, Sanchez-Torres JM, Faul I, Lanman RB, Garrido P, Paz-Ares L
- Issue date: 2019 Feb 1
- Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.
- Authors: Mack PC, Banks KC, Espenschied CR, Burich RA, Zill OA, Lee CE, Riess JW, Mortimer SA, Talasaz A, Lanman RB, Gandara DR
- Issue date: 2020 Jul 15